Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Mar 2023
"You can't treat one of these conditions and ignore the others," says the author of the new review, explaining how obesity can affect the diagnosis and treatment of these heart conditions.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Atezolizumab Consolidation Impresses in High-Risk DLBCL
2.
Breast cancer: Why it's difficult to treat and what new approaches are on the horizon
3.
Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.
4.
Error on the MGUS-Autoimmune Disease Association.
5.
Veterans of the Navy have high lung cancer rates associated with asbestos use.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
3.
The Importance of Balanced Potassium Levels in Maintaining Good Health
4.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
5.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge